SynthesisBMC public health2022
Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review.
Synthesis in BMC public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of demographic and socioeconomic characteristics associated with inequalities in invasive meningococcal disease prevention in high-income countries and Latin America.Human vaccines & immunotherapeutics · 2025Pooled it
- Inequalities in the risk and prevention of invasive meningococcal disease in the United States - A systematic literature review.Human vaccines & immunotherapeutics · 2024Pooled it
- Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.Human vaccines & immunotherapeutics · 2026Trial
- Safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in USA and Puerto Rico: Results from a Phase III, randomized, active-controlled study.Human vaccines & immunotherapeutics · 2026Trial
- Trial
- 4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults.Open forum infectious diseases · 2024Trial
- Parents' and caregivers' views on pediatric meningococcal disease and serogroup B vaccination.Human vaccines & immunotherapeutics · 2026Article
- Health Outcomes, Healthcare Resource Use, and Economic Burden of Invasive Meningococcal Disease in the United States Among Children Aged <11 Years.PharmacoEconomics - open · 2026Article
- Burden of Invasive Meningococcal Disease: Evolving Epidemiology and Implications for Prevention Policy.Infectious diseases and therapy · 2026Review
- Cost-Effectiveness of Routine Infant Meningococcal B Vaccination in the Netherlands.Infectious diseases and therapy · 2026Article
- Review
- Public Health Impact and Cost-Effectiveness of Revising the Adolescent Meningococcal Vaccine Schedule in the United States.PharmacoEconomics · 2026Article
- Epidemiology of invasive meningococcal disease in the United States: review of recent data and identified risk factors.Frontiers in public health · 2026Review
- Modelling the epidemiological impact and cost-effectiveness of possible changes to the meningococcal vaccination schedule for adolescents and young adults in the United States.BMC public health · 2025Article
- Meningococcal vaccination disparities in the United States (2010-2021): Findings from the National Immunization Survey-Teen and a commercial insurance database.Human vaccines & immunotherapeutics · 2025Article
- Invasive meningococcal disease in adolescents in Europe and select geographies: Disease burden, unmet medical need, and optimizing prevention.Human vaccines & immunotherapeutics · 2025Review
- Healthcare costs of invasive meningococcal disease: a nationwide population-based study using an innovative clustering method to identify sequelae.BMC infectious diseases · 2025Article
- Article
- A Ten-Year Retrospective Review of Medical Records of Patients Admitted with Meningitis or Encephalitis at Five Hospitals in the United States Highlights the Potential for Under-Ascertainment of Invasive Meningococcal Disease.Pathogens (Basel, Switzerland) · 2025Article
- Need for Invasive Meningococcal Disease Prevention Through Vaccination for Young Children in the Americas.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInvasive meningococcal disease (IMD) is uncommon, life-threatening, with many diverse sequelae. The aims were to: 1) comprehensively characterise the sequelae; 2) have a systematic application for sequelae impact in economic evaluation (EE).
methodsSequelae categorised as physical/neurological or psychological/behavioural were identified from a systematic review of IMD observational studies (OS) and EEs in high-income countries (published 2001-2020). A comprehensive map and EE-relevant list, respectively, included physical/neurological sequelae reported in ≥2OS and ≥ 2OS + 2EE (≥1OS and ≥ 1OS + 1EE for psychological/behavioural). Sequelae proportions were selected from the highest quality studies reporting most sequelae. Three medical experts independently evaluated the clinical impact of findings.
resultsSixty-Six OS and 34 EE reported IMD sequelae. The comprehensive map included 44 sequelae (30 physical/neurological, 14 psychological/behavioural), of which 18 (14 physical/neurological and 4 psychological/behavioural) were EE-relevant. Experts validated the study and identified gaps due to limited evidence, underreporting of psychological/behavioural sequelae in survivors/their families, and occurrence of multiple sequelae in the acute phase and long-term.
conclusionsThe considerable burden of IMD sequelae on survivors and their families is potentially underestimated in EE, due to underreporting and poorly-defined subtle sequelae. When assessing IMD burden and potential interventions e.g., vaccination, sequelae range and duration, underreporting, and indirect burden on dependents should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.